Best Shopping Centers in Brazil

© 2012 BlogName - All rights reserved.

Firstyme WordPress Theme.
Designed by Charlie Asemota.

How Cancer Treatment Centers of America is Helping Stop Prostate Cancer

December 19, 2017 - Author: steph

Holding free prostate screens are one method in how Cancer Treatment Centers of America is helping to stop prostate cancer in its tracks. Prostate cancer is a leading killer of men in the United States today. With earlier detection, this cancer care institute hopes to drastically lower those figures. Since most prostate cancer symptoms go unnoticed until late in the game, Cancer Treatment Centers of America currently is urging all males middle aged and older to undergo a safe, simple and painless prostate screening to hopefully detect any cancer before current treatment options expire. Labcorp and assorted numbers belonging to the NFL Alumni also participated in last Fall’s free prostate screening drive.

Most healthcare providers working at Cancer Treatment Centers of America got into this field because of a personal experience with cancer. This could be a family member or close friend that influenced their decision to join the ongoing fight. Many others are just caring people who see a need to help others less fortunate in a very practical way. These devoted employees range in age from young to almost retired. Their specialties allow the organization to provide expert care in drug therapies, radiation treatments, dietary concerns, mental and/or emotional health support and so much more.

Cancer Treatment Centers of America has always been among the first to jump on a new cancer treatment option. This motivation to think outside the box is part of the reason why Cancer Treatment Centers of America leads in innovative therapies. They also are dedicated to promoting further educational information learned in their many diverse departments. From holistic nursing care to just discovered research pertaining to a cancer care new treatment, this institute serves as a reminder to never give up where cancer is concerned. Many come to CTCA for renewed hope.

No Comments - Categories: Cancer Therapies, Cancer Treatment

Under leadership of Clay Siegall, Seattle Genetics follows marginal utility maximizing strategy

September 24, 2017 - Author: steph

Almost every successful entrepreneur eventually comes to the realization that the best way to make money is to enter into an industry where one could be a first mover. Examples of successful companies that have done this include Google, Microsoft, Apple and almost every other major innovator that has been able to rise to completely dominate any given industry. The importance of being a first mover and not attempting to compete with long-established and entrenched rivals is one of the most important principles of entrepreneurship.


No one understands this better than the CEO of Seattle Genetics, Clay Siegall. Since founding the firm, in 1998, Clay Siegall has decided to follow a completely novel approach to the treatment of cancer. Rather than attempting to create cancer treatments for cancer types that are already saturated with market solutions, Dr. Siegall has followed a strategy of attempting to treat those cancers that have not seen significant improvements in survivability rates over the last 30 years.


This led Dr. Siegall directly to the cancer type of non-Hodgkin’s lymphoma. This potentially fatal illness of the lymphatic system affects almost 500,000 people in the United States at any given time. Although it has a relatively low mortality rate, by cancer standards, it still kills many thousands of people each year in the United States alone. This is due to its high incidence and the fact that the disease has not seen significant improvements in mortality for well over three decades.


Dr. Siegall chose this disease as a means to prove the concept of his company’s main product, antibody drug conjugates. This highly innovative class of drugs uses synthetic human antibodies as a means to deliver lethal agent to the site of malignant tissues, enabling the drug to almost completely avoid the systemic release of dangerous poisons into the bloodstream that are responsible for the vast majority of side effects associated with modern chemotherapeutic regimes.


The strategy has proven to be a round success, with non-Hodgkin’s lymphoma experiencing one of its first significant survivability improvements in decades. This is largely attributed to the introduction of antibody drug conjugates as a second-line treatment for refractory non-Hodgkin’s lymphoma.

No Comments - Categories: Cancer Treatment